| Literature DB >> 22287812 |
Abstract
Propensity score methods allow investigators to estimate causal treatment effects using observational or nonrandomized data. In this article we provide a practical illustration of the appropriate steps in conducting propensity score analyses. For illustrative purposes, we use a sample of current smokers who were discharged alive after being hospitalized with a diagnosis of acute myocardial infarction. The exposure of interest was receipt of smoking cessation counseling prior to hospital discharge and the outcome was mortality with 3 years of hospital discharge. We illustrate the following concepts: first, how to specify the propensity score model; second, how to match treated and untreated participants on the propensity score; third, how to compare the similarity of baseline characteristics between treated and untreated participants after stratifying on the propensity score, in a sample matched on the propensity score, or in a sample weighted by the inverse probability of treatment; fourth, how to estimate the effect of treatment on outcomes when using propensity score matching, stratification on the propensity score, inverse probability of treatment weighting using the propensity score, or covariate adjustment using the propensity score. Finally, we compare the results of the propensity score analyses with those obtained using conventional regression adjustment.Entities:
Year: 2011 PMID: 22287812 PMCID: PMC3266945 DOI: 10.1080/00273171.2011.540480
Source DB: PubMed Journal: Multivariate Behav Res ISSN: 0027-3171 Impact factor: 5.923
Baseline Characteristics of the Study Sample
| Demographic Characteristics | |||||
| Age | 60.48 ± 13.26 | 56.24 ± 11.26 | 57.61 ± 12.10 | 0.35 | < .001 |
| Female | 220 (29.2%) | 397 (25.0%) | 617 (26.3%) | 0.09 | .032 |
| Presenting Signs and Symptoms | |||||
| Acute pulmonary edema | 34 (4.5%) | 48 (3.0%) | 82 (3.5%) | 0.08 | .067 |
| Vital Signs on Admission | |||||
| Systolic blood pressure | 146.99 ± 31.82 | 146.93 ± 29.92 | 146.95 ± 30.53 | 0.00 | .966 |
| Diastolic blood pressure | 84.81 ± 18.99 | 85.84 ± 18.51 | 85.50 ± 18.67 | 0.06 | .213 |
| Heart rate | 83.28 ± 22.75 | 81.10 ± 22.54 | 81.80 ± 22.63 | 0.10 | .029 |
| Respiratory rate | 21.18 ± 5.75 | 20.18 ± 4.64 | 20.50 ± 5.05 | 0.20 | < .001 |
| Classic Cardiac Risk Factors | |||||
| Diabetes | 179 (23.7%) | 260 (16.4%) | 439 (18.7%) | 0.19 | < .001 |
| Hyperlipidemia | 238 (31.6%) | 539 (33.9%) | 777 (33.2%) | 0.05 | .254 |
| Hypertension | 295 (39.1%) | 541 (34.1%) | 836 (35.7%) | 0.11 | .017 |
| Family history of coronary artery disease | 253 (33.6%) | 754 (47.5%) | 1,007 (43.0%) | 0.28 | < .001 |
| Comorbid Conditions and Vascular History | |||||
| Cerebrovascular accident/Transient ischemic attack | 62 (8.2%) | 67 (4.2%) | 129 (5.5%) | 0.18 | < .001 |
| Angina | 198 (26.3%) | 412 (25.9%) | 610 (26.0%) | 0.01 | .871 |
| Cancer | 22 (2.9%) | 20 (1.3%) | 42 (1.8%) | 0.13 | .005 |
| Dementia | 21 (2.8%) | 6 (0.4%) | 27 (1.2%) | 0.23 | < .001 |
| Previous myocardial infarction | 161 (21.4%) | 241 (15.2%) | 402 (17.2%) | 0.16 | < .001 |
| Asthma | 40 (5.3%) | 98 (6.2%) | 138 (5.9%) | 0.04 | .406 |
| Depression | 76 (10.1%) | 131 (8.2%) | 207 (8.8%) | 0.06 | .145 |
| Peptic ulcer disease | 39 (5.2%) | 111 (7.0%) | 150 (6.4%) | 0.07 | .093 |
| Peripheral vascular disease | 77 (10.2%) | 90 (5.7%) | 167 (7.1%) | 0.18 | < .001 |
| Previous coronary revascularization | 50 (6.6%) | 92 (5.8%) | 142 (6.1%) | 0.04 | .427 |
| Chronic congestive heart failure | 24 (3.2%) | 24 (1.5%) | 48 (2.0%) | 0.12 | .008 |
| Laboratory Tests | |||||
| Glucose | 9.35 ± 5.63 | 8.57 ± 4.79 | 8.82 ± 5.09 | 0.15 | < .001 |
| White blood count | 11.01 ± 4.49 | 10.77 ± 3.55 | 10.85 ± 3.88 | 0.06 | .171 |
| Hemoglobin | 141.71 ± 19.33 | 145.83 ± 15.47 | 144.50 ± 16.92 | 0.24 | < .001 |
| Sodium | 138.75 ± 4.54 | 139.40 ± 3.32 | 139.19 ± 3.77 | 0.17 | < .001 |
| Potassium | 4.10 ± 0.58 | 4.01 ± 0.49 | 4.04 ± 0.52 | 0.16 | < .001 |
| Creatinine | 99.59 ± 62.86 | 89.24 ± 30.24 | 92.57 ± 43.75 | 0.24 | < .001 |
| Prescriptions for Cardiovascular Medications at Hospital Discharge | |||||
| Statin | 193 (25.6%) | 637 (40.1%) | 830 (35.4%) | 0.31 | < .001 |
| Beta-blocker | 460 (61.0%) | 1,192 (75.1%) | 1,652 (70.5%) | 0.31 | < .001 |
| Angiotensin Converting Enzyme (ACE) inhibitor/Angiotensin receptor blockers | 344 (45.6%) | 850 (53.5%) | 1,194 (51.0%) | 0.16 | < .001 |
| Plavix | 29 (3.8%) | 74 (4.7%) | 103 (4.4%) | 0.04 | .37 |
| Acetylsalicyclic Acid (ASA) | 544 (72.1%) | 1,341 (84.4%) | 1,885 (80.5%) | 0.31 | < .001 |
Note. Continuous variables are presented as means ± standard deviation; dichotomous variables are presented as N (%).
Baseline Characteristics of Treated and Untreated Participants in the First Propensity Score Matched Sample
| Demographic Characteristics | ||||
| Age | 59.3 ± 11.8 | 59.5 ± 13.1 | 0.012 | 1.235 |
| Female | 176 (25.8%) | 188 (27.6%) | 0.040 | 1.043 |
| Presenting Signs and Symptoms | ||||
| Acute pulmonary edema | 28 (4.1%) | 29 (4.3%) | 0.007 | 1.034 |
| Vital Signs on Admission | ||||
| Systolic blood pressure | 148.8 ± 31.2 | 147.7 ± 31.2 | 0.036 | 1.002 |
| Diastolic blood pressure | 86.4 ± 18.9 | 85.7 ± 18.5 | 0.036 | 0.952 |
| Heart rate | 83.2 ± 24.4 | 82.5 ± 21.9 | 0.029 | 0.808 |
| Respiratory rate | 20.9 ± 5.3 | 21.0 ± 5.7 | 0.027 | 1.130 |
| Classic Cardiac Risk Factors | ||||
| Diabetes | 149 (21.8%) | 148 (21.7%) | 0.004 | 0.995 |
| Hyperlipidemia | 217 (31.8%) | 218 (32.0%) | 0.003 | 1.002 |
| Hypertension | 276 (40.5%) | 260 (38.1%) | 0.048 | 0.979 |
| Family history of coronary artery disease | 229 (33.6%) | 244 (35.8%) | 0.046 | 1.030 |
| Comorbid Conditions and Vascular History | ||||
| Cerebrovascular accident/Transient ischemic | attack 47 (6.9%) | 45 (6.6%) | 0.012 | 0.960 |
| Angina | 174 (25.5%) | 174 (25.5%) | 0.000 | 1.000 |
| Cancer | 15 (2.2%) | 14 (2.1%) | 0.010 | 0.935 |
| Dementia | 6 (0.9%) | 9 (1.3%) | 0.042 | 1.493 |
| Previous myocardial infarction | 143 (21.0%) | 138 (20.2%) | 0.018 | 0.974 |
| Asthma | 42 (6.2%) | 35 (5.1%) | 0.044 | 0.842 |
| Depression | 64 (9.4%) | 64 (9.4%) | 0.000 | 1.000 |
| Peptic ulcer disease | 36 (5.3%) | 35 (5.1%) | 0.007 | 0.974 |
| Peripheral vascular disease | 64 (9.4%) | 54 (7.9%) | 0.052 | 0.857 |
| Previous coronary revascularization | 45 (6.6%) | 45 (6.6%) | 0.000 | 1.000 |
| Chronic congestive heart failure | 20 (2.9%) | 14 (2.1%) | 0.056 | 0.706 |
| Laboratory Tests | ||||
| Glucose | 9.1 ± 5.4 | 9.2 ± 5.6 | 0.019 | 1.095 |
| White blood count | 10.7 ±i 3.8 | 10.8 ± 4.1 | 0.024 | 1.154 |
| Hemoglobin | 144.2 ± 16.4 | 143.1 ± 18.4 | 0.064 | 1.249 |
| Sodium | 139.0 ± 3.4 | 139.0 ± 3.9 | 0.002 | 1.364 |
| Potassium | 4.1 ± 0.5 | 4.1 ± 0.5 | 0.014 | 1.166 |
| Creatinine | 93.2 ± 38.3 | 93.2 ± 43.9 | 0.001 | 1.310 |
| Prescriptions for Cardiovascular Medications at Hospital Discharge | ||||
| Statin | 184 (27.0%) | 188 (27.6%) | 0.013 | 1.014 |
| Beta-blocker | 425 (62.3%) | 437 (64.1%) | 0.036 | 0.980 |
| Angiotensin Converting Enzyme (ACE) inhibitor/Angiotensin receptor blockers | 335 (49.1%) | 322 (47.2%) | 0.038 | 0.997 |
| Plavix | 30 (4.4%) | 29 (4.3%) | 0.007 | 0.968 |
| Acetylsalicyclic Acid (ASA) | 513 (75.2%) | 514 (75.4%) | 0.003 | 0.996 |
Note. Continuous variables are presented as means ± standard deviation; dichotomous variables are presented as N (%).
Baseline Characteristics of Treated and Untreated Participants in the Final Propensity Score Matched Sample
| Demographic Characteristics | ||||
| Age | 59.1 ± 12.4 | 58.7 ± 12.4 | 0.026 | 0.998 |
| Female | 178 (27.6%) | 175 (27.1%) | 0.010 | 0.989 |
| Presenting Signs and Symptoms | ||||
| Acute pulmonary edema | 31 (4.8%) | 25 (3.9%) | 0.046 | 0.814 |
| Vital Signs on Admission | ||||
| Systolic blood pressure | 147.7 ± 30.5 | 147.8 ± 31.3 | 0.002 | 1.055 |
| Diastolic blood pressure | 85.5 ± 17.7 | 85.7 ± 18.5 | 0.015 | 1.092 |
| Heart rate | 82.1 ± 22.4 | 82.4 ± 22.3 | 0.013 | 0.993 |
| Respiratory rate | 20.8 ± 5.5 | 20.9 ± 5.7 | 0.012 | 1.046 |
| Classic Cardiac Risk Factors | ||||
| Diabetes | 130 (20.1%) | 140 (21.7%) | 0.038 | 1.056 |
| Hyperlipidemia | 216 (33.4%) | 214 (33.1%) | 0.007 | 0.995 |
| Hypertension | 247 (38.2%) | 247 (38.2%) | 0.000 | 1.000 |
| Family history of coronary artery disease | 218 (33.7%) | 235 (36.4%) | 0.055 | 1.035 |
| Comorbid Conditions and Vascular History | ||||
| Cerebrovascular accident/Transient ischemic attack 39 (6.0%) | 46 (7.1%) | 0.044 | 1.166 | |
| Angina | 165 (25.5%) | 166 (25.7%) | 0.004 | 1.004 |
| Cancer | 15 (2.3%) | 13 (2.0%) | 0.021 | 0.869 |
| Dementia | 5 (0.8%) | 8 (1.2%) | 0.047 | 1.593 |
| Previous myocardial infarction | 131 (20.3%) | 131 (20.3%) | 0.000 | 1.000 |
| Asthma | 33 (5.1%) | 35 (5.4%) | 0.014 | 1.057 |
| Depression | 63 (9.8%) | 63 (9.8%) | 0.000 | 1.000 |
| Peptic ulcer disease | 30 (4.6%) | 30 (4.6%) | 0.000 | 1.000 |
| Peripheral vascular disease | 57 (8.8%) | 57 (8.8%) | 0.000 | 1.000 |
| Previous coronary revascularization | 44 (6.8%) | 43 (6.7%) | 0.006 | 0.979 |
| Chronic congestive heart failure | 13 (2.0%) | 14 (2.2%) | 0.011 | 1.075 |
| Laboratory Tests | ||||
| Glucose | 9.0 ± 5.3 | 9.1 ± 5.5 | 0.011 | 1.075 |
| White blood count | 10.9 ±i 3.9 | 10.7 ± 3.6 | 0.038 | 0.863 |
| Hemoglobin | 143.2 ± 16.7 | 143.9 ± 17.6 | 0.041 | 1.117 |
| Sodium | 139.1 ± 3.5 | 139.0 ± 3.3 | 0.025 | 0.920 |
| Potassium | 4.0 ± 0.5 | 4.1 ± 0.5 | 0.004 | 1.151 |
| Creatinine | 93.8 ± 39.6 | 92.1 ± 40.2 | 0.045 | 1.033 |
| Prescriptions for Cardiovascular Medications at Hospital Discharge | ||||
| Statin | 189 (29.3%) | 185 (28.6%) | 0.014 | 0.987 |
| Beta-blocker | 424 (65.6%) | 427 (66.1%) | 0.010 | 0.993 |
| Angiotensin Converting Enzyme (ACE) inhibitor/Angiotensin receptor blockers | 302 (46.7%) | 309 (47.8%) | 0.022 | 1.002 |
| Plavix | 24 (3.7%) | 28 (4.3%) | 0.031 | 1.159 |
| Acetylsalicyclic Acid (ASA) | 476 (73.7%) | 488 (75.5%) | 0.043 | 0.953 |
Note. Continuous variables are presented as means ± standard deviation; dichotomous variables are presented as N (%).
FIGURE 1Comparing distribution of continuous covariates in propensity-score matched sample.
FIGURE 2Comparing distribution of continuous covariates in inverse probability of treatment weighted sample.
FIGURE 3Quantile regression to compare conditional distribution of baseline covariates between treatment groups.
FIGURE 4Kaplan-Meier survival curves in matched and weighted samples.
FIGURE 5Kaplan-Meier survival curves in PS strata.
Comparison of Effect Sizes Across Different Propensity Score Methods
| Propensity score matching | 0.0185 (−0.018, 0.055) | 0.88 (0.69, 1.13) |
| Stratification on the propensity score—5 strata | 0.035 (0.006, 0.063) | 0.75 (0.59, 0.96) |
| Stratification on the propensity score—10 strata | 0.027 (−0.002, 0.056) | 0.80 (0.63, 1.03) |
| Weighting—first estimator | 0.020 (−0.008, 0.047) | 0.86 (0.66, 1.01) |
| Weighting—doubly robust estimator | 0.025 (−0.002, 0.052) | 0.82 (0.66, 1.03) |
| Covariate adjustment using the propensity score | 0.023 (−0.005, 0.052) | 0.84 (0.68, 1.04) |